Ixekizumab for the treatment of ankylosing spondylitis

References

• Khan MA, van der Linden S. Axial spondyloarthritis: a better name for an old disease: a step toward uniform reporting. ACR Open Rheumatol. 2019;1(5):336–339.
   PubMedGoogle Scholar
• Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369(9570):1379–1390.
   PubMed Web of Science ®Google Scholar
• Ranganathan V, Gracey E, Brown MA, et al. Pathogenesis of ankylosing spondylitis - recent advances and future directions. Nat Rev Rheumatol. 2017;13:359e67.
   Web of Science ®Google Scholar
• Ward MM, Deodhar A, Gensler LS, et al. Update of the American College of Rheumatology/Spondylitis Association of America/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599‐1613.
   Web of Science ®Google Scholar
• Sepriano A, Regel A, van der Heijde D, et al. Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open. 2017;3:e000396.
   PubMed Web of Science ®Google Scholar
• Moreno M, Gratacós J, Torrente-Segarra V, et al. Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study. Arthritis Res Ther. 2019;21(1):88.
   PubMed Web of Science ®Google Scholar
• Karmacharya P, Duarte-Garcia A, Dubreuil M, et al. Effect of therapy on radiographic progression in axial spondyloarthritis: a systematic review and meta-analysis. Arthritis Rheumatol. 2020;72(5):733–749.
   PubMed Web of Science ®Google Scholar
• Haroon N, Inman RD, Learch TJ, et al. The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013;65:2645e54.
   Google Scholar
• Maas F, Arends S, Wink FR, et al. Ankylosing spondylitis patients at risk of poor radiographic outcome show diminishing spinal radiographic progression during long-term treatment with TNF-alpha inhibitors. PLoS One. 2017;12:e0177231.
   PubMed Web of Science ®Google Scholar
• Molnar C, Scherer A, Baraliakos X, et al. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss clinical quality management cohort. Ann Rheum Dis. 2018;77:63e9.
   Web of Science ®Google Scholar
• Taltz (Ixekizumab), packager insert. Mechanism of action, pharmacodynamics and pharmacokinetics of IXE. IN, USA: Eli Lilly and Company; 2018.
   Google Scholar
• Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum. 2009;60:1647–1656.
   PubMed Web of Science ®Google Scholar
• Ono T, Okamoto K, Nakashima T, et al. IL-17-producing gd T cells enhance bone regeneration. Nat Commun. 2016;7:1–9.
   Web of Science ®Google Scholar
• Fragoulis GE, Siebert S, McInnes IB. Therapeutic targeting of IL-17 and IL-23 cytokines in immune-mediated diseases. Annu Rev Med. 2016;67:337‐353.
   PubMed Web of Science ®Google Scholar
• Liu L, Lu J, Allan BW, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016;9:39‐50.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Cheng-Chung Wei J, Dougados M, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392(10163):2441‐2451.
   Web of Science ®Google Scholar
• Brandt J, Listing J, Sieper J, et al. Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis. 2004;63:1438–1444.
   PubMed Web of Science ®Google Scholar
• Anderson JJ, Baron G, van der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 2001;44:1876–1886.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Poddubnyy D, Pacheao-tena C, et al. Effificacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a Phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheumatol. 2019;71(4):599–611.
   PubMed Web of Science ®Google Scholar
• Dougados M, Wei JC, Landewé R, et al. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis. 2020;79(2):176‐185.
   Web of Science ®Google Scholar
• Mease P, Walsh JA, Baraliakos X, et al. Translating improvements with Ixekizumab in clinical trial outcomes into clinical practice: ASAS40, pain, fatigue, and sleep in ankylosing spondylitis. Rheumatol Ther. 2019;6(3):435‐450.
   Web of Science ®Google Scholar
• European Medicine Agency. Cosentyx: EPAR -Summary for the public. EMEA/H/C/003729; [ updated 2015 Mar 2; cited 2019 Dec 4]. Available from: https://www.ema.europa.eu/en/documents/overview/cosentyx-epar-summarypublic_en.pdf
   Google Scholar
• Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US; [ updated 2016 Jan 15; cited 2019 Dec 5]. Available from: https://novartis.gcs-web.com/novartis-receives-fda-approvals-for-secukinumab-in-as-and-psa
   Google Scholar
• European Medicine Agency. Taltz: EPAR summary for the public. EMEA/H/C/003943; 2016 Apr 25 [updated 2019 Aug 28; cited 2019 Dec 7]. Available from: https://www.ema.europa.eu/en/documents/overview/taltz-epar-summary-public_en.pdf
   Google Scholar
• Eli-Lilly press release. FDA approves Taltz for treatment of ankylosing spondylitis; [ updated 2019 Aug 26; cited 2019 Dec 7]. Available from: https://investor.lilly.com/news-releases/news-release-details/lilly-receives-us-fda-approval-taltzr-ixekizumab treatment
   Google Scholar
• Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373:2534–2548.
   PubMed Web of Science ®Google Scholar
• Baeten D, Baraliakos X, Braun J, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382:1705–1713.
   PubMed Web of Science ®Google Scholar
• Pavelka K, Kivitz A, Dokoupilova E, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther. 2017;19(1):285.
   PubMed Web of Science ®Google Scholar
• Marzo-Ortega H, Sieper J, Kivitz A, et al. Secukinumab and sustained improvement in signs and symptoms of patients with active ankylosing spondylitis through two years: results from a phase III study. Arthritis Care Res (Hoboken). 2017;69(7):1020–1029.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Braun J, Deodhar A, et al. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. RMD Open. 2019;5(2):e001005.
   PubMed Web of Science ®Google Scholar
• Kivitz AJ, Wagner U, Dokoupilova E, et al. Efficacy and safety of secukinumab 150 mg with and without loading regimen in ankylosing spondylitis: 104-week results from MEASURE 4 study. Rheumatol Ther. 2018;5(2):447–462.
   PubMed Web of Science ®Google Scholar
• Wei JC, Baeten D, Sieper J, et al. Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies. Int J Rheum Dis. 2017;20(5):589–596.
   PubMed Web of Science ®Google Scholar
• Blair HA. Secukinumab: a review in ankylosing spondylitis. Drugs. 2019;79(4):433–443.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Gensler LS, Deodhar A, et al. Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2020;79(5):595–604.
   PubMed Web of Science ®Google Scholar
• Silacci M, Lembke W, Woods R, et al. Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases. MAbs. 2016;8(1):141–149.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54:2136–2146.
   PubMed Web of Science ®Google Scholar
• Huang F, Gu J, Zhu P, et al. Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial. Ann Rheum Dis. 2014;73:587–594.
   PubMed Web of Science ®Google Scholar
• Wei JC, Zhang LJ, Huang JX. Placebo responses in ankylosing spondylitis patients worldwide: variations and possible explanations. Expert Rev Clin Immunol. 2020;16(5):447–450.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Negrini S, Magnani O, et al. Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis. Expert Opin Drug Saf. 2017;16(10):1173–1179.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Gulli R, Spanò F, et al. Pharmacogenetics and future therapeutic scenarios: what affects the prediction of response to treatment with etanercept? Drug Dev Res. 2014;75(Suppl 1):S7–S10.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Gulli R, Spanò F, et al. TNF-α gene polymorphisms: association with disease susceptibility and response to anti-TNF-α treatment in psoriatic arthritis. J Invest Dermatol. 2014;134(10):2503–2509.
   PubMed Web of Science ®Google Scholar
• van Vugt LJ, van den Reek JMPA, Meulewaeter E, et al. Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts. J Eur Acad Dermatol Venereol. 2020;34(1):112–118.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Negrini S, Greco M, et al. Immunogenicity of infliximab and adalimumab. Expert Opin Drug Saf. 2019;18(5):343–345.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spanò F, Contatore M, et al. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety? Expert Opin Drug Saf. 2016;15(1):43–52.
   PubMed Web of Science ®Google Scholar
• Spindeldreher S, Maillère B, Correia E, et al. Secukinumab demonstrates significantly lower immunogenicity potential compared to Ixekizumab [published correction appears in dermatol ther (Heidelb). Dermatol Ther (Heidelb). 2018;8(1):57–68.
   PubMed Web of Science ®Google Scholar
• Spindeldreher S, Karle A, Correia E, et al. T cell epitope mapping of secukinumab and ixekizumab in healthy donors. MAbs. 2020;12(1):1707418.
   PubMed Web of Science ®Google Scholar